Skip to content
Cultural Foundation
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 14, 2026
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 12, 2026
Rigel Reports First Quarter 2026 Financial Results
May 5, 2026
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
April 28, 2026
←
Previous Page
1
2